| Nome |
# |
|
Antidiabetic drugs in NAFLD: The accomplishment of two goals at once?, file e3ad891e-ef11-da0e-e053-3705fe0a2b96
|
150
|
|
Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma, file e3ad8925-b798-da0e-e053-3705fe0a2b96
|
145
|
|
Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-analysis, file e3ad8921-7aa4-da0e-e053-3705fe0a2b96
|
140
|
|
The burden of hepatocellular carcinoma in non-alcoholic fatty liver disease: Screening issue and future perspectives, file e3ad8920-83a9-da0e-e053-3705fe0a2b96
|
124
|
|
Pharmacological therapy of non-alcoholic fatty liver disease: What drugs are available now and future perspectives, file e3ad8920-85d4-da0e-e053-3705fe0a2b96
|
114
|
|
Optimizing sequential systemic therapies for advanced hepatocellular carcinoma: A decision analysis, file e3ad8922-df8f-da0e-e053-3705fe0a2b96
|
102
|
|
Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use, file e3ad8924-dbbc-da0e-e053-3705fe0a2b96
|
91
|
|
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease, file e3ad8920-83a3-da0e-e053-3705fe0a2b96
|
70
|
|
Competing-risk analysis of coronavirus disease 2019 in-hospital mortality in a Northern Italian centre from SMAtteo COvid19 REgistry (SMACORE), file e3ad8926-eefc-da0e-e053-3705fe0a2b96
|
69
|
|
Identification of clinical phenotypes and related survival in patients with large hccs, file e3ad8927-d56b-da0e-e053-3705fe0a2b96
|
52
|
|
Surveillance as determinant of long-term survival in non-transplanted hepatocellular carcinoma patients, file e3ad8927-bbe7-da0e-e053-3705fe0a2b96
|
43
|
|
Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment, file e3ad8927-dd14-da0e-e053-3705fe0a2b96
|
42
|
|
First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials, file e3ad8927-f1d5-da0e-e053-3705fe0a2b96
|
38
|
|
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib, file e3ad8927-bdef-da0e-e053-3705fe0a2b96
|
35
|
|
Outcomes of hepatocellular carcinoma patients treated with sorafenib: A meta-analysis of Phase III trials, file e3ad8927-abaf-da0e-e053-3705fe0a2b96
|
30
|
|
Radiomics Analysis on Gadoxetate Disodium-Enhanced MRI Predicts Response to Transarterial Embolization in Patients with HCC, file eb19d031-2b61-4f0b-a5e6-f1e3dee82fb9
|
24
|
|
Risk profiling of hepatocellular carcinoma occurrence after eradication
of hepatitis C virus with direct-acting antiviral agents, file 55e1505e-cd98-4cc8-bbce-25702fad7c17
|
22
|
|
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints, file cd7a0e37-141f-45ab-9caa-19d414fdddfd
|
19
|
|
Telemedicine Is an Effective Tool to Monitor Disease Activity in IBD Patients in the COVID-19 Era: A Single Centre Experience Based on Objective Data, file 5b4e07a6-119b-4c96-8af1-e39e2d4587d8
|
12
|
|
Impact of biliary stents on the diagnostic accuracy of EUS-guided fine-needle biopsy of solid pancreatic head lesions: A multicenter study, file e3ad8927-8098-da0e-e053-3705fe0a2b96
|
12
|
|
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib, file e3ad8927-fe4b-da0e-e053-3705fe0a2b96
|
12
|
|
Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation, file b95960f1-0933-4958-a5c4-4dbf44cce0b5
|
11
|
|
Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals, file c784078a-7428-4ca7-be17-667c00cf3385
|
11
|
|
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease, file e3ad8926-7f4c-da0e-e053-3705fe0a2b96
|
10
|
|
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs, file d485a90a-8f8e-4e80-b514-5542f2466fef
|
9
|
|
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices, file 86d1e742-6aec-43f8-b349-32d4e87bfae6
|
8
|
|
Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence, file e3ad8927-fe4a-da0e-e053-3705fe0a2b96
|
8
|
|
Reply, file 6e10c240-bb93-4fd6-abe1-6902c9077322
|
7
|
|
Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-analysis, file b65f2698-031e-402b-a963-5240bbd08e95
|
7
|
|
AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD, file 252d801d-6541-408b-8b1f-f1f5e313157d
|
6
|
|
Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study, file 28bec8b0-2af6-45a0-8ab7-3dbf18829309
|
6
|
|
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma, file a4fce8e3-6525-4ea6-b4d9-2cef9e45a172
|
6
|
|
The relevance of noninvasive tools to assess fibrosis in non-alcoholic fatty liver disease, file c947572c-c7dc-4fb9-88c5-6c239387cea3
|
6
|
|
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients, file e3ad8921-8e4f-da0e-e053-3705fe0a2b96
|
6
|
|
Sicily Network for Liver Cancer: A Multidisciplinary Network Model for the Management of Primary Liver Tumors, file e3ad8927-13f6-da0e-e053-3705fe0a2b96
|
6
|
|
Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis, file f387914d-6a4e-4659-ac64-86b3e41d5b59
|
5
|
|
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib, file 0f25ff58-f919-4d7f-90c2-7ef9ef42700c
|
4
|
|
Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model, file dd42994e-737f-40ae-9c4b-ef8c000976fe
|
4
|
|
Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals, file e3ad8927-20b0-da0e-e053-3705fe0a2b96
|
4
|
|
Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19, file e3ad8927-bbe9-da0e-e053-3705fe0a2b96
|
4
|
|
Consequences of Extended Spectrum Beta-Lactamase–Producing Enterobacteriaceae and Methicillin-Resistant Staphylococcus aureus Carriage in Awaiting Liver Transplant Patients, file e3ad8927-c03e-da0e-e053-3705fe0a2b96
|
4
|
|
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept, file 2276beb2-1fdd-481d-bfaf-0133094c0dfc
|
3
|
|
Reply, file 5c49ccbe-1bb8-4e09-bb69-f3400f7bb90b
|
3
|
|
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy, file b2824342-cc18-4d52-ac53-c1e3fcb6846d
|
3
|
|
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis, file e3ad8926-f7dd-da0e-e053-3705fe0a2b96
|
3
|
|
Efficacy of lumen-apposing metal stents or self-expandable metal stents for endoscopic ultrasound-guided choledochoduodenostomy: A systematic review and meta-analysis, file e3ad8927-8097-da0e-e053-3705fe0a2b96
|
3
|
|
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon, file eb4c6e01-b41a-41d0-a3a9-fbef407fd5c2
|
3
|
|
Reply, file 5ff3398d-0966-4de8-bc50-c3899293f413
|
2
|
|
COSMIC-312: mounting immunotherapy enigmas for hepatocellular carcinoma, file 7645b905-0574-4f96-aa38-7e33a573197d
|
2
|
|
Textbook Outcome After Trans-arterial Chemoembolization for Hepatocellular Carcinoma, file 78591410-0273-4cda-929a-6db4a8a42858
|
2
|
|
Reliability of grading preoperative pancreatic neuroendocrine tumors on EUS specimens: a systematic review with meta-analysis of aggregate and individual data, file 88d3b934-c401-457f-b679-a6663cbfb722
|
2
|
|
The price and value of therapeutic synergy in liver cancer, file 8b2384b1-5432-4374-8091-4f771463c827
|
2
|
|
Expert opinion vs. meta-analysis: To be or not to be?, file dd82a8d3-776b-437f-b21d-c8fa7391d129
|
2
|
|
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients, file e3ad891e-e05d-da0e-e053-3705fe0a2b96
|
2
|
|
Diagnostic performance of endoscopic ultrasound through-the-needle microforceps biopsy of pancreatic cystic lesions: Systematic review with meta-analysis, file e3ad8927-984d-da0e-e053-3705fe0a2b96
|
2
|
|
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy, file e3ad8927-99f0-da0e-e053-3705fe0a2b96
|
2
|
|
Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study, file e3ad8927-a612-da0e-e053-3705fe0a2b96
|
2
|
|
Biochemical biomarkers of NAFLD/NASH, file e3ad8928-45b0-da0e-e053-3705fe0a2b96
|
2
|
|
Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison, file 84c4098b-2617-4596-8a44-84d68bf7e2ae
|
1
|
|
Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?, file e3ad891e-b3a3-da0e-e053-3705fe0a2b96
|
1
|
|
Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma?, file e3ad8921-82fc-da0e-e053-3705fe0a2b96
|
1
|
|
Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?, file e3ad8926-eefe-da0e-e053-3705fe0a2b96
|
1
|
|
Biliary complications after liver transplantation: current perspectives and future strategies, file e3ad8927-c9d7-da0e-e053-3705fe0a2b96
|
1
|
|
Through-the-needle biopsy of pancreatic cystic lesions: stronger evidences of higher diagnostic yield compared with cytology, file e3ad8927-e302-da0e-e053-3705fe0a2b96
|
1
|
| Totale |
1.524 |